
Preventive healthcare startup Cent secured $15 million in a Series A round co-led by Blume Ventures and South Park Commons to expand its AI‑driven early disease detection platform and fund the acquisition of Medsee.
Cent, a preventive healthcare startup based in India, announced a $15 million Series A funding round co‑led by Blume Ventures and South Park Commons. The round also included individual investors Arun Sarin, Srinivas Narayanan, Sharath Narayana, Aprameya Radhakrishna and Krishan Sridhar, as disclosed by founder Shashank ND in a LinkedIn post.
The capital infusion follows Cent’s recent acquisition of the AI radiology platform Medsee, strengthening its technology stack.
Cent’s platform targets early disease detection by combining full‑body magnetic resonance imaging, low‑dose computed tomography, DEXA scans, electrocardiograms, echocardiograms and more than 100 biomarkers into a single two‑hour session. The company reports that around 10,000 individuals have undergone its screening protocol, with one in four receiving findings that required medical attention and one in 40 needing immediate doctor consultation.
Operating its own centres in Bengaluru, Mumbai and Delhi NCR, alongside a network of partner diagnostic labs, Cent aims to scale its services to conduct 10 million scans by 2035 and save one million lives through early detection.
The $15 million Series A will be deployed to expand hardware capacity, enhance artificial‑intelligence capabilities and fund clinical research initiatives. Investment in these areas is intended to accelerate the rollout of Cent’s comprehensive screening protocol across additional locations and to integrate Medsee’s AI radiology tools into its diagnostic workflow.
The capital also supports the company’s broader ambition to address gaps in India’s healthcare system, where non‑communicable diseases often go undiagnosed until advanced stages.
Founded by Shashank ND, who previously founded the healthcare platform Practo, Cent focuses on preventive health through a data‑driven, AI‑enabled screening process. The startup’s protocol merges advanced imaging techniques with a wide array of biomarkers, delivering a holistic health assessment in a single visit.
Since its inception, Cent has built proprietary centres in three major Indian cities and partnered with diagnostic labs to broaden its reach.
The Series A proceeds will fund the acquisition of additional imaging hardware, the development of AI algorithms for improved diagnostic accuracy, and expanded clinical research to validate the efficacy of Cent’s screening regimen. Capital will also support geographic expansion, enabling the launch of new centres beyond the current Bengaluru, Mumbai, and Delhi NCR footprint.
Blume Ventures and South Park Commons co‑led the round, bringing deep expertise in early‑stage technology investments. Individual backers Arun Sarin, Srinivas Narayanan, Sharath Narayana, Aprameya Radhakrishna and Krishan Sridhar also participated, signaling confidence in Cent’s vision to transform preventive healthcare in India.
Cent operates within the health technology sector, specifically focusing on preventive diagnostics, AI‑enhanced imaging, and biomarker‑driven disease detection.